Drug Profile
Bethanechol transmucosal - Acacia Pharma
Alternative Names: APD 515Latest Information Update: 13 Jun 2022
Price :
$50
*
At a glance
- Originator Acacia Pharma
- Class Neuroprotectants; Small molecules; Trimethyl ammonium compounds
- Mechanism of Action Muscarinic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Xerostomia
Most Recent Events
- 09 Jun 2022 Acacia Pharma has been acquired by Eagle Pharmaceuticals
- 07 Aug 2019 Discontinued - Phase-II for Xerostomia in Denmark (Transmucosal)
- 07 Aug 2019 Discontinued - Phase-II for Xerostomia in United Kingdom (Transmucosal)